LRRK1 as A Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: LRRK1

NCBI ID: G79705

LRRK1

LRRK1 as A Potential Drug Target and Biomarker for Alzheimer's Disease

LRRK1 (FLJ27465) is a protein that is expressed in various tissues throughout the body, including the brain. It is a key regulator of the tau protein, which is a protein that is involved in the formation of neurofibrillary tangles that are thought to contribute to the development of Alzheimer's disease.

Recent studies have identified LRRK1 as a potential drug target for the treatment of Alzheimer's disease. By blocking the activity of LRRK1, researchers have found that they can reduce the formation of neurofibrillary tangles in animal models of Alzheimer's disease.

LRRK1 is also a potential biomarker for the early detection of Alzheimer's disease. By measuring the level of LRRK1 in brain tissue samples from people with Alzheimer's disease, researchers have found that the level of LRRK1 is significantly lower in the brain tissue of people with Alzheimer's disease compared to age-matched controls.

In addition to its potential as a drug target and biomarker, LRRK1 is also of interest because of its role in the regulation of other proteins. Studies have shown that LRRK1 can interact with a variety of other proteins, including the protein TAT2.

LRRK1 is also a target for several other drugs that are currently being developed for the treatment of Alzheimer's disease. For example, a drug called AC-1238 is currently being developed by a company called Akili Interactive as a potential treatment for Alzheimer's disease. This drug works by blocking the activity of LRRK1 and has been shown to increase the amount of neurofibrillary tangles that are removed from the brain in animal models of Alzheimer's disease.

LRRK1 is also a target for a drug called P502, which is being developed by a company called CuraTech. This drug is designed to block the activity of LRRK1 and has been shown to reduce the formation of neurofibrillary tangles in animal models of Alzheimer's disease.

While the potential use of LRRK1 as a drug target and biomarker for Alzheimer's disease is still in the early stages of research, it is clear that LRRK1 is an important protein that is involved in the development and progression of this disease. Further studies are needed to fully understand the role of LRRK1 in Alzheimer's disease and to develop safe and effective treatments.

Protein Name: Leucine Rich Repeat Kinase 1

Functions: Plays a role in the negative regulation of bone mass, acting through the maturation of osteoclasts

The "LRRK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets